Description
Disarib is a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain, demonstrates strong affinity to BCL2, but not to other antiapoptotic BCL2 family members (BCL-xL, BCL2A1 etc.); is a novel BCL2 inhibitor with a unique mechanism of BCL2 inhibition